# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The focus of this new research agreement is to develop an enhanced formulation of Travelan potentially expanding the coverage o...
Sales Highlights: Global•FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp)•June 2024 Quarter AUD$1.3 million up...
-6-K
To address this need, Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics f...
Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. Durin...
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced p...
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expecte...
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to a...